{
  "@context": "aku-v2",
  "@type": "concept",
  "@id": "medicine:vascular:pathology:thrombophilia:thrombophilia-001",
  "metadata": {
    "version": "1.0.0",
    "created": "2026-01-05T05:10:00.000Z",
    "contributors": [
      "copilot"
    ],
    "confidence": 0.95,
    "status": "enhanced",
    "board_yield": "HIGH",
    "modified": "2026-01-09T11:29:00.000Z"
  },
  "classification": {
    "domain_path": "health-sciences/medicine/surgery/vascular/pathology/thrombophilia",
    "type": "definition",
    "difficulty": "advanced",
    "importance": "high"
  },
  "content": {
    "title": "Thrombophilia (Hypercoagulable States)",
    "definition": "Inherited or acquired conditions that predispose to venous or arterial thrombosis. Important consideration in unprovoked venous thromboembolism, recurrent thrombosis, unusual site thrombosis, or family history of VTE.",
    "key_concepts": [
      {
        "term": "Inherited Thrombophilias",
        "description": "Factor V Leiden (most common); Prothrombin G20210A mutation; Protein C deficiency; Protein S deficiency; Antithrombin deficiency (highest risk)"
      },
      {
        "term": "Factor V Leiden",
        "description": "Most common inherited thrombophilia (5% Caucasians); point mutation causes resistance to activated protein C; heterozygotes have 3-8x VTE risk; homozygotes 80x risk"
      },
      {
        "term": "Prothrombin Gene Mutation",
        "description": "G20210A mutation; second most common; 2-3% Caucasian prevalence; 3x increased VTE risk; elevated prothrombin levels"
      },
      {
        "term": "Antithrombin Deficiency",
        "description": "Highest risk inherited thrombophilia (25-50x VTE risk); may cause heparin resistance (need higher doses); argatroban preferred for anticoagulation"
      },
      {
        "term": "Protein C/S Deficiency",
        "description": "Vitamin K-dependent natural anticoagulants; deficiency increases VTE risk 5-10x; warfarin-induced skin necrosis can occur (especially protein C) from early drop in these factors"
      },
      {
        "term": "Acquired Thrombophilias",
        "description": "Antiphospholipid syndrome (most important); malignancy; myeloproliferative neoplasms; PNH; HIT; pregnancy; oral contraceptives"
      },
      {
        "term": "Antiphospholipid Syndrome",
        "description": "Antibodies against phospholipid-binding proteins; lupus anticoagulant, anticardiolipin, anti-\u03b22-glycoprotein I; arterial and venous thrombosis; recurrent pregnancy loss; requires lifelong anticoagulation"
      },
      {
        "term": "Testing Indications",
        "description": "Unprovoked VTE at young age (<50); recurrent VTE; unusual site thrombosis (cerebral, splanchnic); strong family history; arterial thrombosis without atherosclerosis"
      },
      {
        "term": "Testing Limitations",
        "description": "Do not test during acute thrombosis (protein C/S falsely low); do not test on anticoagulation (affects many assays); results rarely change management"
      },
      {
        "term": "Management Implications",
        "description": "Extended anticoagulation for high-risk thrombophilias (AT deficiency, APS, homozygous FVL); family screening controversial; does not affect acute treatment"
      }
    ],
    "clinical_features": {
      "snomed_codes": [
        "441634007",
        "234467004"
      ],
      "icd_10_codes": [
        "D68.5",
        "D68.6",
        "D68.8"
      ],
      "symptoms": [
        "Recurrent VTE",
        "VTE at unusual sites",
        "Pregnancy complications"
      ],
      "signs": [
        "DVT/PE",
        "Cerebral vein thrombosis",
        "Portal vein thrombosis",
        "Warfarin-induced skin necrosis"
      ],
      "risk_factors": [
        "Family history VTE",
        "Young age at first VTE",
        "Recurrent VTE",
        "Unusual site thrombosis"
      ]
    },
    "differential_diagnosis": [
      "Acquired hypercoagulability (cancer, immobility)",
      "May-Thurner syndrome",
      "Catheter-related thrombosis",
      "Paroxysmal nocturnal hemoglobinuria"
    ],
    "statement": "Thrombophilia (Hypercoagulable States) is a fundamental concept in Health-Sciences Medicine Surgery Vascular Pathology Thrombophilia that provides essential knowledge for understanding related topics and clinical/practical applications.",
    "explanation": {
      "intuition": "Understanding Thrombophilia (Hypercoagulable States) helps build foundational knowledge. The concept connects to broader principles in the field.",
      "key_insight": "The key aspects of Thrombophilia (Hypercoagulable States) include core principles, common applications, and integration with related concepts.",
      "technical_details": "Technical details involve specific mechanisms, measurements, and evidence-based applications of Thrombophilia (Hypercoagulable States)."
    }
  },
  "relationships": {
    "skos:broader": [
      "medicine:hematology:coagulation-disorders"
    ],
    "skos:related": [
      "medicine:vascular:pathology:dvt",
      "medicine:vascular:pharmacology:anticoagulation:ac-001",
      "medicine:rheumatology:antiphospholipid-syndrome"
    ],
    "skos:narrower": []
  },
  "pedagogical": {
    "learning_objectives": [
      "Classify inherited vs acquired thrombophilias",
      "Know Factor V Leiden as most common inherited thrombophilia",
      "Understand antiphospholipid syndrome requires lifelong anticoagulation",
      "Recognize when thrombophilia testing is indicated"
    ],
    "clinical_pearls": [
      "Factor V Leiden = most common (5% Caucasians)",
      "Antithrombin deficiency = highest risk (25-50x) + heparin resistance",
      "Protein C/S deficiency \u2192 warfarin skin necrosis risk",
      "Don't test during acute VTE or on anticoagulation (affects results)",
      "Antiphospholipid syndrome = lifelong anticoagulation (high recurrence)",
      "Testing rarely changes acute management"
    ],
    "common_mistakes": [
      "Testing during acute thrombosis (false results)",
      "Testing while on anticoagulation",
      "Testing every VTE patient (most have provoked VTE)",
      "Starting warfarin without bridging in protein C/S deficiency"
    ]
  },
  "provenance": {
    "citations": [
      {
        "source": "UpToDate. (2024). Thrombophilia (Hypercoagulable States). Wolters Kluwer.",
        "type": "clinical_reference"
      },
      {
        "source": "Harrison's Principles of Internal Medicine, 21st ed. McGraw-Hill.",
        "type": "textbook"
      }
    ],
    "verification_status": "pending",
    "last_verified": null
  }
}